Verdict91/ 100
Grade A− · #2Eden
A polished, high-disclosure compounded program with strong nationwide coverage.
Visit EdenHead-to-head verdict
Eden vs Gala Health
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict86/ 100
Grade B · #8Gala Health
One of the few names on the board that pairs a genuinely cheap compounded entry with a real brand-Ozempic path and nationwide coverage — the verdict docks it only for a sky-high brand sticker and an oral route it doesn't yet offer.
Visit Gala HealthThe verdict
Winner: Eden
Eden takes it with a higher Verdict Score — 91/100 to 86/100 (grade A− vs B). People who prioritize a vetted, high-transparency provider over the lowest sticker price. Gala Health still earns its place — patients in any state who want to start on low-cost compounded tirzepatide but keep a legitimate brand-name option on the table.
Neither of these is our overall #1. That title goes to CoreAge Rx (94/100) — the most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
90Real-world results85
90
Real-world results85
89Price honesty87
89
Price honesty87
95Prescriber access88
95
Prescriber access88
86Formulary choice88
86
Formulary choice88
90Cancellation fairness84
90
Cancellation fairness84
92Member support84
92
Member support84
Price, coverage & features
| Metric | Eden | Gala Health |
|---|---|---|
| Verdict Score | 91/100 | 86/100 |
| Grade | A− | B |
| Semaglutide | $239/mo | Not disclosed |
| Tirzepatide | $349/mo | $179/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | No |
Eden
What we like
- High verification confidence — clear supply-chain and clinician disclosure
- Nationwide availability
- Both molecules offered
The caveats
- Premium pricing vs the cheapest tiers
- Compounded only — no brand-name access
Gala Health
What we like
- Low compounded entry — tirzepatide at $179/mo, microdose at $149/mo, and a 3-month plan from $199/mo
- Available in all 50 states, so access never blocks the sign-up
- Offers a real FDA-approved brand path (Ozempic) alongside the compounded track — rare on this list
- Adjacent HRT and menopause care for patients who want more than a GLP-1 alone
The caveats
- GLP-1 is compounded, not FDA-approved — the standard verification caveat applies
- Brand Ozempic runs $1,299/mo — the brand path exists but is priced out of reach for most
- No oral or sublingual option yet
- Newer operator (AI Coaching Inc) with a thin public track record — vet the pharmacy yourself
Our pick — visit
People who prioritize a vetted, high-transparency provider over the lowest sticker price.
Visit Eden Read the full Eden review →Also worth a look
Patients in any state who want to start on low-cost compounded tirzepatide but keep a legitimate brand-name option on the table.
Visit Gala Health Read the full Gala Health review →Keep comparing
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.